Results 261 to 270 of about 12,956,457 (322)

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

Molecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon, Dong Young Kim, Yuna Kim, Uk‐Il Kim, Jae‐Sung Kim   +4 more
wiley   +1 more source

RaMBat: Accurate identification of medulloblastoma subtypes from diverse data sources with severe batch effects

Molecular Oncology, EarlyView.
To integrate multiple transcriptomics data with severe batch effects for identifying MB subtypes, we developed a novel and accurate computational method named RaMBat, which leveraged subtype‐specific gene expression ranking information instead of absolute gene expression levels to address batch effects of diverse data sources.
Mengtao Sun, Jieqiong Wang, Shibiao Wan
wiley   +1 more source

Persistent Neuroendocrine Function is Still Vegetative: A Reply to Berendes. [PDF]

Linacre Q
DeCock CA, Feikles CF, Thomas C, Donovan GK, Tornatore CS, Sulmasy DP.   +5 more
europepmc   +1 more source

Tracking Chart 2004 Eddie Bauer, USA 02008258C [PDF]

, 2004
Fair Labor Association
core   +1 more source

Colorectal cancer‐derived FGF19 is a metabolically active serum biomarker that exerts enteroendocrine effects on mouse liver

Molecular Oncology, EarlyView.
Meta‐transcriptome analysis identified FGF19 as a peptide enteroendocrine hormone associated with colorectal cancer prognosis. In vivo xenograft models showed release of FGF19 into the blood at levels that correlated with tumor volumes. Tumoral‐FGF19 altered murine liver metabolism through FGFR4, thereby reducing bile acid synthesis and increasing ...
Jordan M. Beardsley, Michael W. Rohr, Joseph A. Goode, Sai Preethi Nakkina, Jignesh G. Parikh, Deborah A. Altomare   +5 more
wiley   +1 more source

Integrating the Glycemia Risk Index Into Clinical Practice and Research: A Consensus Report. [PDF]

J Diabetes Sci Technol
Umpierrez GE, Shah VN, Brady V, Clements MA, Espinoza J, Healey E, Kohn MA, Maahs DM, Oiknine R, Seley JJ, Weitzman SP, Kerr D, Akturk HK, Aleppo G, Al-Sofiani ME, Cengiz E, Doyle FJ, Ebekozien O, Edelman SV, Ekhlaspour L, Freckmann G, Heinemann L, Hirsch IB, Hsiao VC, Kim SH, Kovatchev B, Lal RA, Lind M, Mader JK, Mathioudakis N, McLaughlin T, Meo SA, Osafehinti DA, Phillip M, Prahalad P, Scheinker D, Snyder MP, Wang J, Wong JC, Wright EE, Shao MM, Scheideman AF, DuNova AY, Klonoff DC.   +43 more
europepmc   +1 more source

Auswirkungen einer Importsteuer in den USA - Wer zahlt für die "Mauer"?

, 2017
Christian Pierdzioch, Georg Stadtmann
openalex   +1 more source

Topographic Change from Lidar in Eastern Kentucky, USA (2012–2023, 2017-2023): Datasets covering the July 2022 Storm

Scheip, Corey, Weidner, Luke, Graham, Alexander, Hsiao, Vicky, Winters, Susan   +4 more
openalex   +1 more source

Identification of serum protein biomarkers for pre‐cancerous lesions associated with pancreatic ductal adenocarcinoma

Molecular Oncology, EarlyView.
This work identified serum proteins associated with pancreatic epithelial neoplasms (PanINs) and early‐stage PDAC. Proteomics screens assessed genetically engineered mice with abundant PanINs, KPC mice (Lox‐STOP‐Lox‐KrasG12D/+ Lox‐STOP‐Lox‐Trp53R172H/+ Pdx1‐Cre) before PDAC development and also early‐stage PDAC patients (n = 31), compared to benign ...
Hannah Mearns, Jaclyn S. Long, Sergio Lilla, Kelly Hodge, Marcus J. G. W. Ladds, Colin Nixon, Paula Fernández‐Palanca, Sara Zanivan, Pilar Acedo, Stephen P. Pereira, Kevin M. Ryan   +10 more
wiley   +1 more source

Advancing the science of nucleic acids together. [PDF]

Mol Ther Nucleic Acids
Schiefelbein B, Giangrande PH, Chen Z.
europepmc   +1 more source